Overview

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Status:
Recruiting

Trial end date:
2024-05-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene

Treatments:

Obinutuzumab
Rituximab